Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, Phase I study

Authors

Luis Paz-Ares, Universidad Complutense de Madrid
Ramaswamy Govindan, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

6-1-2023

Volume

41

Issue

16

First Page

2893

Last Page

2903

Document Type

Open Access Publication

DOI

10.1200/JCO.22.02823

Rights and Permissions

Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903. doi: 10.1200/JCO.22.02823. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: http://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Paz-Ares, Luis; Govindan, Ramaswamy; and et al., "Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, Phase I study." Journal of Clinical Oncology. 41, 16. 2893 - 2903. (2023).
https://digitalcommons.wustl.edu/oa_4/2190

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.